Navigation Links
Biodel Inc. Added to NASDAQ Biotechnology Index
Date:5/13/2008

DANBURY, Conn., May 13 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) today announced that the Company has been selected for inclusion in the NASDAQ Biotechnology Index (NBI), effective as of the market's open on Monday, May 19, 2008.

"We are pleased to be included in the NASDAQ Biotechnology Index and believe Biodel's inclusion is a result of the Company's consistent achievement of its goals," stated Dr. Solomon Steiner, Chairman and Chief Executive Officer of Biodel. "We look forward to reporting on future 2008 goals including the results from our two pivotal Phase III clinical trials for VIAject(TM) in September or October and the filing of our NDA submission for a suite of VIAject(TM) presentations by the end of 2008."

Launched in 1993, the NBI includes biotechnology and pharmaceutical companies listed on the NASDAQ National Market that meet minimum requirements for market value, average daily share volume and seasoning as a public company. The index is ranked on a semi-annual basis in May and November and serves as the basis for the iShares Nasdaq Biotechnology Index Fund (Amex: IBB). For more information about the Nasdaq Biotechnology Index, including eligibility criteria, visit http://www.nasdaq.com.

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for endocrine disorders, such as diabetes and osteoporosis. Biodel's product candidates are developed by using VIAdel(TM) technology, which reformulates existing FDA- approved peptide drugs. The Company's lead product candidate, VIAject(TM), is an ultra rapid-acting injectable meal-time insulin in development for use by patients with Type 1 or Type 2 diabetes. VIAject(TM) is currently being tested in two pivotal Phase III clinical trials. Biodel's pipeline also includes VIAtab(TM), a sublingual tablet formulation of insulin in the Phase I stage of clinical testing, and two pre-clinical osteoporosis product candidates. For further information regarding Biodel, please visit the Company's website at http://www.biodel.com.

BIOD-G


'/>"/>
SOURCE Biodel Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results
2. Biodel Inc. to Present at the Bank of America 2008 Health Care Conference on May 13th 2008
3. Biodel Inc. to Present at the Morgan Stanley Global Healthcare Unplugged Conference April 30th 2008
4. Biodel Inc. to Present at the BioCentury Future Leaders Conference on March 27th, 2008
5. Biodel Inc. Reports First Quarter Fiscal Year 2008 Financial Results
6. Biodel Inc. to Announce First Quarter Fiscal Year 2008 Financial Results on February 14, 2008
7. Biodel Inc. Announces Pricing of Public Offering
8. Biodel to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on December 11, 2007
9. Brian J.G. Pereira, M.D. Joins Biodels Board of Directors
10. Biodel Inc. to Present at Natixis Bleichroeder Hidden Gems Conference on October 8, 2007
11. Biodel Inc. to Present at BIO InvestorForum 2007 Conference on October 11, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... 25, 2017 , ... LABS, Inc. (LABS) announced in December 2016 that ... menu: Nucleic Acid Testing (NAT) for ZIKV; and Enzyme Immunoassays (EIAs) specific for IgM ... screening for blood donors under an Investigational New Drug (IND) study protocol. , ...
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... ... headlines and drive high-level conversations among healthcare industry stakeholders, the discussion surrounding the ... – taking place May 15-18, 2017 in Los Angeles, Calif. Hosted by the ...
(Date:4/25/2017)... ... 25, 2017 , ... Franz Inc ., an early ... and market leader for Semantic Graph Database technology, today announced ... most effective system for developing and deploying applications to solve the challenges developers ...
(Date:4/25/2017)... ... 2017 , ... Dr. Robert G. Schwartz, the principal of ... that acclaimed physiatrist Matthew Terzella, MD, has joined the practice as a partner, ... completed his residency in Physical Medicine and Rehabilitation at UMDNJ-Robert Wood Johnson and ...
Breaking Biology Technology:
(Date:3/24/2017)... , March 24, 2017 The Controller General ... Controller Mr. Abdulla Algeen have received the prestigious international IAIR ... Continue Reading ... ... picture) and Deputy Controller Abdulla Algeen (small picture on the right) have ...
(Date:3/23/2017)... DUBLIN , Mar. 23, 2017 Research ... Anti-Theft System Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 8.8% over the next ... This industry report analyzes the market estimates and forecasts for all ...
(Date:3/22/2017)... Vigilant Solutions , a vehicle location ... announced today the appointment of retired FBI special agent ... business development. Mr. Sheridan brings more than ... focus on the aviation transportation sector, to his new ... Sheridan served as the Aviation Liaison Agent Coordinator (ALAC) ...
Breaking Biology News(10 mins):